secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0000950170-24-113631
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports positive ODYSSEY Phase 2b results for CLS-AX in wet AMD; all endpoints met
--------------------------------------------------------------------------------

- ODYSSEY Phase 2b trial of suprachoroidal CLS-AX achieved primary and secondary outcomes; stable BCVA and CSRT through 36 weeks.
- 67% of CLS-AX participants required no additional treatment up to 6 months; 90% up to 4 months, 81% up to 5 months.
- Treatment burden reduced by ~84% compared to average monthly injections prior to screening.
- No ocular or treatment-related SAEs; no endophthalmitis, no retinal vasculitis; well-tolerated safety profile.
- Company plans to advance CLS-AX into Phase 3 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024113631/0000950170-24-113631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024113631/clsd-20241009.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer